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INTRODUCTION 
 
INTRODUCTION- VITILIGO SURGERIES 
        The main intention of the any vitiligo surgery is to repigment the 
vitiligenous areas with a natural colour of the individual by various means: 
 Simulating the natural colour by tattooing1, a method in which 
artificial pigments are introduced by microneedling technique. 
 Using a thin Theirsch's2 graft to cover the denuded achromic areas. 
 Various grafts, e.g. ultra-thin grafts3, suction blister4 and miniature 
punch grafts5, non-cultured epidermal cell suspension or 
transplantation, and epidermal6 and melanocyte cultures7 can be 
used to repopulate the decreased melanocytes. 
 The lesional melanocytes can be stimulated from the periphery 
and the black hair follicles to proliferate, migrate and re-pigment 
the lesion by Therapeutic wounding8 e.g. therapeutic 
dermabrasion, laser ablation, cryosurgery (liquid nitrogen 
spraying), needling, and local application of phenol or 
trichloroacetic acid. 
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AIM AND OBJECTIVES OF THE STUDY 
 
 
1. To compare the effect of split skin grafting   versus miniature punch 
grafting in vitiligo patients. 
2. To look for the adverse effects during these procedures. 
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REVIEW OF LITERATURE 
 
History12: 
 
  
 The origin of the word vitiligo has many proposed meanings.  The 
Rigveda (6000 BC or earlier) named it as Kilas, meaning white spotted 
deer9. In Buddhist sacred books also it was named as Kilas. Some believed 
it to be originated from `vitelius’ meaning vale, i.e. pale pink flesh of calf 
because of its clinical resemblance to the white patches of the spotted 
calf. Few others think it has its origin in Latin word `vitium’ meaning 
blemish. 
 
Epidemiology: 
 
 Vitiligo affects almost all races in the world.  The worldwide 
incidence ranges from 0.1 to 1.3%10,11. In India it varies from 3-4% to as 
high as 8.8%. 
 
Definition12: 
 
Vitiligo is an acquired progressive melanocytopenia of unknown 
etiology, clinically manifested by circumscribed achromic macules often 
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associated with leukotrichia and histologically by degeneration and 
disappearance of melanocytes in the involved skin and not infrequently in 
the pigment epithelium of the eyes, leptomeninges and inner ear. 
 
 
Etiopathogenesis:  
 
THE CLASSIC HYPOTHESES: 
Autoimmune theory: 
 
This is the most popular theory citing that melanocytes are killed by 
autoimmune effector mechanisms. The association of other autoimmune 
disorders like pernicious anemia, autoimmune thyroiditis, Addison’s 
disease supports this theory13. The first clue for participation of cellular 
immunity in vitiligo pathogenesis was the discovery of T-cell infiltrate in 
the margin of the inflammatory vitiligo.  Following successful 
immunotherapy of melanoma, vitiligo like depigmentation has been 
noted. Humoral immunity too has  a role and various circulating 
autoantibodies against Tyrosinase, TRP-1, TRP-2, etc. are found with their 
titres well correlating with disease activity. 
 
11 
 
The Neural Hypothesis: 
 
This theory suggests that destruction of melanocytes due to 
alteration in the ratio of the neurotransmitters or due to liberation of 
unusual neurotransmitter. The occurrence of vitiligo in segmental pattern 
and anecdotal reports of its origin after viral encephalitis, following 
peripheral nerve injury, its association with multiple sclerosis and 
Horner`s syndrome further supports this. Communication between 
nervous system and epidermal melanocytes has been proved14. 
 
The autocytotoxic theory: 
 
 
Lerner15,in the year 1971 postulated that melanocytes have a 
genetically based  protective mechanism that eliminates toxic products 
like DOPA, DOPAchrome  and 5,6-dihydroxyindole which are produced 
during the synthesis of Melanin. Some people who are deficient in these 
mechanisms have accumulation of these melanotoxic products, which 
result in depigmentation.  
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THE NEW HYPOTHESES: 
  
A disorder of melanocyte survival: 
 
The involvement of melanocyte apoptosis and of SCF16/c-kit/MITF/Bcl-2  
 
pathway in the pathogenesis of vitiligo indicates their key role in the  
 
maintenance of melanocyte survival.  
 
 
a) SCF from keratinocytes strongly protects melanocytes  from TNF-
related apoptosis inducing ligand(TRAIL) 
b) Bcl-2, a MITF-dependent kit transcriptional target in melanocytes, is 
essential for maintaining the lifetime of melanocytes. When Bcl-2 
expression is decreased, the susceptibility of the melanocytes to 
apoptosis increases.  
c) Down regulated expression of c-kit and MITF-M proteins at the 
edges of lesional vitiligo epidermis have been confirmed by 
Western blotting, 
 
The melanocyte growth factor deficiency theory: 
 
Partial correction of the defective growth and passage capacities of vitiligo 
melanocytes by the adjunction of fetal lung fibroblasts-derived growth 
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factors suggests that the decreased concentration of melanocyte growth 
factor(s) could play a role in the pathogenesis of vitiligo17. 
 
Melanocyte defective adhesion:  
 
Interaction between melanocytes and basement membrane zone 
are mediated by α6β1 integrins. Cadherins and β-catenin helps the 
interaction between the keratinocytes and melanocytes. Repeated friction 
in non-lesional skin of vitiligo patients induces detachment and 
transepidermal elimination18 of melanocytes indicating the probable 
cause of koebnerization. 
All hypotheses are not mutually exclusive. 
 
Consequence theory19: 
 
It suggests that genetic factors, stress, accumulation of toxic 
compounds, autoimmunity, infection, altered cellular environment and 
impaired melanocyte migration and proliferation can all contribute to the 
phenomenon of vitiligo. 
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COMPOSITE THEORY OF PATHOGENESIS12 
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 Understanding the mechanism of repigmentation in vitiligo: 
The nature of repigmentation can be classified into three types: 
a) Perifollicular when predominant repigmentation is follicular 
b) Marginal, when the predominant repigmentation is from the border 
of the patches 
c) Diffuse pigmentation when there occurs generalized darkening 
across the patches of the vitiligo. 
MECHANISMS OF MEDICALLY INDUCED REPIGMENTATION: 
PERIFOLLICULAR REPIGMENTATION20: 
Three stages: 
1) Proliferation of hypertrophic melanocytes in the lower portion of 
hair follicle 
2) Migration of hypertrophic melanocytes along the hair follicle 
toward the infundibulum 
3) Migration of melanocytes to the adjacent epidermis 
The melanocyte mitogens- basic fibroblast growth factor, stem cell factor 
and endothelin-1 have been shown to stimulate melanocyte migration 
which may be either chemotactic or chemokinetic. Matrix 
metalloproteinases are found to be involved in extracellular matrix 
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remodeling and in cell migration during physiological and pathological 
processes. 
 
Diffuse repigmentation: 
 
Jarrett and Szabo21 suggested that reactivation of dihydroxyphenylalanine 
(DOPA) negative melanocytes which persist in the center of lesions might 
be responsible for diffuse type of repigmentation. 
 
Marginal repigmentation19: 
 
A topically applied drug has chemo-attractant action for melanocytes, 
which attracts large reservoir of normal melanocytes surrounding the 
depigmented patch of vitiligo. Those melanocytes gradually migrate and 
actively produce melanin. 
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Mechanisms of surgically induced repigmentation: 
The aim of surgical induction of repigmentation is  
   To replenish melanocytes in the depigmented lesions of vitiligo which 
have no reservoir or which fail to activate melanocyte in the outer root 
sheath with known treatment modalities19. 
 
The various mechanisms by which this happens are 
 
1) Altered milieu of epidermal cytokines caused by a simple 
dermabrasion can stimulate inactive melanocytes of outer root 
sheath. These melanocytes which are seen in the epidermis 8-10 
days after dermabrasion are 2-3 times larger than normal 
melanocytes with a hypertrophic cellular body, elongated 
dendrites, and intense DOPA oxidase activity. 
2) In minigrafting, the tiny miniature grafts acts as islands of 
melanocyte reservoir19, which stimulates hair follicle reservoir. The 
Perigraft pigmentation originating from these minigrafts spread 
generally 5-10 mm beyond the graft margin. 
3) The ability of the melanocytes to migrate plays a role in surgical 
grafting either through suction blister grafting or epidermal 
grafting. The graft take is not necessary for successful 
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repigmentation22. The contact of graft with denuded recipient 
vitiligenous area for 7-8 days causes melanocyte migration from the 
graft to graft bed and causes success. 
4) In transplantation of melanocyte-keratinocyte cell suspension or in 
cultured “pure” melanocytes, diffuse repigmentation occurs 
because of even repopulation of melanocytes to the recipient 
area19. 
 
 Classification of vitiligo: 
Broadly vitiligo can be classified into vitiligo vulgaris and vitiligo 
pseudosegmentalis. 
 
According to the distribution of lesions it can be divided into localized and 
generalized type. 
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Table 1 Classification of vitiligo according to the distribution of lesions19 
1. Localized  
(a)  Focal 
(b) Segmental 
(c) Mucosal 
2. Generalized 
(a) Acrofacial 
(b)  Vulgaris 
(c) Universal 
(d)  Mixed 
Segmental type is usually localized to one dermatome, shows relatively 
stable  
disease activity after its initial rapid-spreading phase, and is associated 
with a significantly lower rate of autoimmune diseases than non-
segmental type. 
Table 2 Classification of vitiligo with emphasis on segmental vitiligo19. 
1. Segmental (unilateral) 
2. Non-segmental (bilateral) 
(i) Localized 
(a) Focal 
(b) Mucosal 
       (ii)Generalized 
(a) Acrofacial 
(b) Vulgaris 
(c) Universal 
3. Mixed: segmental and non-segmental 
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Clinical features of non-segmental (bilateral) vitiligo: 
This type includes all types of vitiligo other than segmental.  
 
Focal vitiligo: 
 
This type exhibits one or more macules in one area, but not clearly 
in a segmental or zosteriform distribution. Focal vitiligo is a starting point 
leading to other types of vitiligo. Without treatment it frequently spreads 
to the whole body. However early treatment will not guarantee 
prevention of its spread.  Systemic steroids effectively prevent the spread 
of this type. 
 
Mucosal vitiligo:  
 
Vitiligo of lips, gingival, genitals, areolae and nipples occur in this 
type. Significant progression of vitiligo in patients with mucosal 
involvement indicates poor prognosis. 
 
Acrofacial vitiligo: 
 
This encompasses vitiligo lesions in the distal part of the extremities 
(hands, feet) and circumferential lesions around facial orifices. 
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Vitiligo vulgaris: 
This entity is composed of several scattered macules. 
  
Universal vitiligo: 
In this type loss of pigment is seen >80% body surface.  
 
Clinical features of Segmental vitiligo: 
This has an earlier onset and spreads rapidly within the affected 
area. But it is limited to one segment example: face, part of trunk and 
extremity or one extremity. The lesions stop abruptly at the midline of the 
affected segment. After the cessation of the progression the vitiligo patch 
remain without any change for the life of the patient. Very rarely it can 
progress again after being quiescent for many years. Studies on its 
distribution show it most commonly involves trigeminal nerve, followed 
by the thoracic, cervical, lumbar and sacral nerves. However the actual 
depigmentation will not correlate very well to a true dermatome. They 
may represent an unknown pathway of group of identical clonal cells.  
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Involvement of other pigment epithelium: 
Destruction of the pigment epithelium in the retina and the outer 
choroids may give a tigroid appearance. Scarring too can occur and 
impairs visual acuity.  The pigment epithelium of inner ear and 
leptomeninges can also get involved.  
 
Associated skin disorders12: 
Alopecia areata 
Atopic eczema 
Psoriasis 
Scleroderma 
Lichen planus 
Lichen simplex 
Discoid lupus erythematosus 
Halo nevus 
Ichthyosis vulgaris 
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Associated systemic disorders12: 
Pernicious anemia 
Addison`s disease 
Grave`s disease 
Hyperthyroidism 
Hypothyroidism 
Thyroiditis 
Hyperparathyroidism 
Diabetes mellitus 
Internal malignancy 
 
Factors affecting vitiligo progression: 
Physical trauma 
Sunburn 
Psychological stress 
Pregnancy  
Contraceptives 
 
 
 
24 
 
 
Medical treatment: 
Phototherapy:  
 
This include photochemotherapy ( oral and topical) such as 
psoralen plus UVA (PUVA), Psoralen plus sunlight (PUVASOL), broadband 
and narrowband UVB (BB- and NB-UVB), 308-nm excimer light and 
combination phototherapy. 
 
UVA phototherapy: 
Topical PUVA photochemotherapy: 
 
This therapy is usually restricted to vitiligo patients with an 
involvement of less than 20% of the body surface19. One percent 8 
methoxypsoralen (8-MOP) is diluted from 1:10 to 1:100. This should be 
applied only to the areas of depigmentation with a cotton tip applicator 
taking care that it should not drip to the normal areas. The patient is 
exposed to UVA approximately 20-30 minutes after application. 
 
The initial dose should not exceed 0.25J/cm2. This treatment is 
given once or twice a week. It should never be given on two consecutive 
days. Dose increments in the range of 0.12-0.25J/cm2/week can be done, 
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until mild erythema is achieved at the treated sites. Following treatment, 
the area is washed thoroughly. A broad spectrum sunscreen is applied and 
excessive sun exposure should be avoided for at least 24 hours23.  
 
In PUVASOL therapy, where sunlight is used as a source of UVA 
there are more chance of blistering. In one study done by Grimes PE, only 
3% had blistering reactions out of 125 patients who had home based 
PUVASOL therapy where very dilute 8-MOP (0.001%) was used. 
 
Oral PUVA photochemotherapy:  
 
PUVA involves the use of psoralens followed by exposure to long-
wavelength UVA irradiation. Oral Trimethoxypsoralen (TMP) is preferred 
to 8-Methoxypsoralen (more phototoxic) and 5-Methoxypsoralen (less 
effective).  The dose of it is 0.6mg/kg body weight ingested along with 
food. After 2 hours, the area is exposed to approximately 3 J/cm2 of UVA 
for 5 minutes. The exposure time can be gradually raised until erythema 
beginning about 12-18 hours after exposure, and maximal at 48 hour is 
achieved after each exposure12, with a twice a week treatment. If 
repigmentation is not seen even after 20-39 treatments of 45 minutes 
exposure to each site, the dose of TMP is increased to 0.9mg/kg body 
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weight. If the desired results are still not achieved after another 20-30 
treatments, the drug is changed to 0.3mg/kg body weight of     8-MOP.  
 
The irradiance of light is measured in milliwatts/cm2 (mw/cm2) with 
the help of an appropriately calibrated radiometer. The dose of UVA 
irradiance is expressed in joules/cm2 (J/cm2).  The following formula is 
employed to calculate exposure time in minutes for the desired dose in 
joules. 
 
Exposure time (min) = Prescribed UVA dose (J/cm2) 
                                        0.06 X Irradiance (mw/cm2) 
 
The following points should be kept in mind while on PUVA therapy: 
 Treatment can be given twice or thrice a week, but never on two 
consecutive days. 
 Therapy usually needs to be continued for 9-19 months. 
 For satisfactory improvement it has been estimated at least 150-
300 exposures may be needed. 
 It should be avoided in patients less than 12 years of age, during 
pregnancy and lactation, and in patients with a past history of 
photosensitivity or X-ray therapy. 
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 Concurrent treatment with potential photosensitizing drugs should 
be avoided. 
 Ophthalmological check up should be done initially and periodically. 
 Hematological status, renal and hepatic functions are to be 
assessed initially and periodically during the period of therapy. 
 
UVB therapy: 
 
Broadband UVB lamps emit light in a broad range which can be 
helpful and also responsible for increased chance of phototoxicity and skin 
cancers. 
Narrow band UVB has overcome all these side effects and is very 
effective24. The emission spectrum of NB-UVB is 311nm. The starting dose 
varies from 100 to 250 mJ/cm2. Increments of about 10 to 20% can be 
done with each subsequent exposure.  
 
The advantages of NB-UVB therapy are 
 No oral medication needed so no side effects of Psoralen. 
 Can be used in pregnancy and children. 
 No post exposure eye protection is necessary. 
 Exposure time is shorter than with PUVA. 
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Excimer laser: 
 
The 308-nm xenon chloride excimer laser is found to be useful in 
chronic stable vitiligo, with studies claiming good results in short period of 
time. Its given twice or thrice weekly for 10-15 sittings. Initial 
pigmentation is seen within 4-8 weeks. But treatment for >12 weeks only 
gives satisfactory repigmentation. 
 
Other modes of photochemotherapy includes 
Khellin with UVA exposure 
Phenylalanine with UVA exposure 
Calcipotriol with PUVA therapy. 
 
Corticosteroids: 
 
Topical corticosteroids are the first line of treatment in patients 
with a few localized lesions.  With mid potent and super potent topical 
corticosteroids like mometasone, betamethasone, clobetasol marked to 
complete repigmentation has occurred25.  
 
It is applied once or twice daily for 6-8 weeks followed by treatment 
free interval of several weeks. After 3 months if there is no 
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repigmentation, this treatment has to be stopped.  The exact mechanism 
of steroid induced repigmentation is not known. The proposed 
hypotheses are may be due to suppression of immunity driven 
melanocyte destruction and stimulation of melanocyte proliferation and 
migration19. Side effects include skin atrophy, acne, ecchymosis, 
telengiectasia, rosacea and striae. To avoid these side effects steroids 
should be applied only for limited area and uninterrupted prolonged use 
should be avoided. 
 
Systemic steroids- high dose pulse, oral mini pulse and daily oral 
low dose have been claimed to give good results in generalized vitiligo 
vulgaris. The long list of side effects of corticosteroids should always be 
borne in mind. 
Calcineurin inhibitors: 
 
Tacrolimus 0.1% and Pimecrolimus 1% ointments have been found 
to be effective in both localized and generalized vitiligo26,27. In a 2 month 
double-blind randomized trial, both tacrolimus and clobetasol have given 
equal results only28. But topical calcineurin inhibitors give good results in 
sun exposed areas19.  
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Immunomodulators: 
 
Levamisole, anapsos, Isoprinosine and suplatast were the 
immunomodulators  with some preliminary studies showing some 
efficacy. Unfortunately, the initial observations in the efficacy of these 
compounds in the treatment of vitiligo have not been followed by clinical 
studies. As a consequence, these agents have not been widely used by 
vitiligo patients. 
 
Others: 
 
Antioxidants like tocopherols, ascorbic acid, ubiquinone and 
selenium methionine are widely prescribed by many dermatologists to 
arrest the spread of vitiligo and to promote its repigmentation. But till 
date the use of these agents are not validated by any controlled clinical 
trial. 
 
Anecdotal report of claiming good repigmentation with topical 
prostaglandin E2 (PGE2)29 have to be confirmed with further studies.   
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Surgical therapy: 
 
In the middle of 20th century, Spencer and Tolmach30 harvested 
punch grafts from normal skin and grafted it in to the vitiligenous skin in 
the year 1952.  Following that there were many similar trials were done, 
but with inconsistent results. They were unable to predict who will 
repigment and who will not. 
Various types of surgeries were tried and extensively studied. Basically 
five groups of procedures have been described since initial trials were 
done. They are  
 
1) Thin dermo-epidermal grafts 
2) Epidermal grafting 
3) Minigrafting 
4) Epidermal suspensions 
5) In vitro cultures of epidermis with melanocytes and melanocyte 
suspensions 
 
Thin split-thickness skin grafts: 
 
This surgical technique was first introduced by Ollier in 1872 and 
Thiersch in 18742. In this method, dermo-epidermal grafts harvested with 
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a knife or dermatome in vitiligo patients. Split thickness grafts are taken 
and grafted over dermabraded achromic vitiligenous areas. 
  
Epidermal grafting: 
In the year 1971, for the first time Falabella4 prepared epidermal grafts 
by suction blistering and he succeeded in treating segmental vitiligo 
and depigmentation in post-burn injury. At present, epidermal grafting 
is one of the most popular techniques used with great success for 
vitiligo repigmentation. 
 
Minigrafting (Miniature Punch grafting): 
This technique was also described by Falabella31 in 1983. This method 
was designed to simulate the pigmentation response occuring during 
perifollicular repigmentation in vitiligo after medical treatment, a 
method that is particularly successful for patients with stable vitiligo. 
Small minigrafts of 1-1.2mm were harvested with a punch from hidden 
donor sites, such as the gluteal region and implanted at the recipient 
sites, where similar perforations were made to prepare the recipient 
sites.  
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Epidermal suspensions: 
This effective method was initially described by Gauthier and Surleve-
Bazeille32 in the year 1992. The epidermal suspension was obtained by 
exposing thin dermo-epidermal sheet to a 0.25% trypsin solution. After 
enzymatic digestion, the epidermal cells became separated individually 
forming a cell suspension that was seeded on the denuded achromic 
area. 
 
In vitro cultures of epidermis with melanocytes and melanocyte 
suspensions: 
In 1989, Falabella6 et al cultured for the first time epidermis with 
melanocytes for the purpose of repigmentation. Epidermal layers 
successfully grown on Eagle`s minimal essential medium, 
supplemented with pituitary extract and hormones, were applied to 
patients with satisfactory results. 
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Figure 1- Classification of various surgical techniques employed in patients 
with vitiligo and other leukodermas19. 
 
 
 
 
Surgical therapies for vitiligo 
    Autologous grafting techniques Non grafting techniques 
Tissue grafts Cellular grafts 
Laser  micropigmentation 
Full thickness punch 
grafting/minigrafting 
Split-thickness grafting 
Suction blister grafts 
Hair follicle grafts 
Seed grafts 
Flip top graft 
Non-cultured-keratinocyte and melanocyte cell suspension 
       Cultured autografts 
Cultured melanocytes 
Cultured epithelial grafts 
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MINIGRAFTS- Full thickness punch grafts: 
Procedure:  
A punch biopsy, encompassing both the epidermis and the dermis, is used 
as a graft. 
 
Preparation of recipient site: 
Small perforations are performed after local anaesthesia with a biopsy 
punch of 1.2-2.5mm. The perforations should be of 0.5-1mm deep and be 
separated from each other by 3-5mm. the achromic plugs are pulled out 
and the recipient area is covered with normal saline compresses. When 
the treated is large and many perforations are anticipated, a motor driven 
mini-punch device is helpful to prepare the recipient site. Pulsed Er:YAG 
(erbium: yttrium-aluminium-garnet) laser was proposed as an alternative 
to punch biopsy to prepare the recipient site. 
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Harvesting of grafts and grafting: 
Perforations are performed with a punch of similar size as for recipient 
site, at a distance of about 1mm from each other. Some recommend 
taking a punch biopsy 0.25-0.5mm larger in diameter than the recipient 
site because of the retraction of the graft site. Grafts are freed from the 
donor site and excess adipose tissue is trimmed to achieve a thickness 
equal to the depth of recipient pits. Grafts are inserted into the small 
perforations, held in place with steri-strips and covered by a non-adherent 
dressing for approximately 1 week. Sunlight exposure or PUVA helps in 
stimulation of pigment spread. 
Repigmentation around punch grafts usually starts 2-3 weeks after graft 
placement. Coalescence of pigment from all punch grafts occurs within 4-
6 months. Good repigmentation has been achieved in 68-82% of cases.  
Advantages: 
Easiest  
Least expensive 
No special equipment  
Suitable for difficult locations- lips, palms, soles and fingers 
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Disadvantages: 
Time consuming for large areas 
Regrafting between the transplanted grafts may be necessary 
Not suitable for body folds 
 
Split-thickness grafts: 
Procedure: 
A sheet of skin of 0.2-0.3 mm thickness, thus consisting almost exclusively 
of epidermis, is used as a graft. 
 
Harvesting of grafts: 
The split–thickness graft is harvested after local anaesthesia, with razor 
blade/manual or motorized dermatome. 
Recipient site preparation and grafting: 
The recipient area is denuded by dermabrasion or by CO2 laser. Grafts of 
approximately 4-5 cm length are placed over the denuded recipient site 
close to another with slight overlap. Grafts are held in place with staples 
or steri-strips, and covered with a non-adherent sterile dressing for 
approximately 1 week.  
This technique gives good results provided the graft is very thin.  
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Advantages: 
Suitable to cover large areas at one time 
Suitable for difficult areas- eyelids and lips 
 
Disadvantages: 
Good skill is needed to take a uniformly thin graft 
Not possible to cover palms, soles and body folds. 
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MATERIALS AND METHODS 
Study Design 
• Type of study: Non randomized prospective comparative study 
 
Study Population: 
 
• Sample Size:   50 patients divided into 2 groups  
 
Study period:  
 
           July 2010- October 2011 (15 months) 
          First 6 months:  Interventional period 
          Next 9 months: Follow-up period 
 
Study analysis: 
Results analysis- chi square test using spsf software 
 
Place of study: 
 
        Department of Dermatology, 
        Government Stanley Medical College & Hospital,  
        Chennai.  
 
From almost 400 vitiligo patients attending our OP (both old and 
new patients), 50 patients were selected according to the inclusion and 
exclusion criteria. They were enquired about the duration of their 
problem, any new lesions in the recent past or any new lesions occuring at 
the sites of trauma. They were examined meticulously and carefully 
looked for any erythema or evidence of koebnerization.  Out of the 50 
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patients, 20 patients with mucosal vitiligo over lips, 28 patients with focal 
vitiligo over dorsum of foot/hand, eyelid, cheeks, forearm and legs, 1 
segmental vitiligo and 1 acrofacial vitiligo patients were included in the 
study. They were given pre-treatment consultation, information sheet 
about the surgical procedure and fully explained about the pros and cons 
of the surgery. After their full understanding and willingness only they 
were enrolled in the study. Pre-operative assessment and investigations 
were done. 
Pre-treatment consultation:  
 
Patients were well informed about the method of the procedure, course 
of the treatment and possible adverse effects. 
Informed and written consent were obtained. 
A complete history regarding the onset, duration, any other co-existing 
systemic illnesses, and past history of any treatment taken for this 
condition were noted (ANNEXURE-I). 
Proper counseling of the patient is very important. It should be 
emphasized that skin grafting cannot stop progression of the disease but 
only provides a pigmentary cover. The disease may recur. Immediate 
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results may not be cosmetically acceptable and color matching with 
surrounding normal skin can take up to 1-6 months. 
 
PRE-SURGERY ASSESSMENT: 
A thorough clinical examination as given in ANNEXURE-I was done. 
Patients BCG scar was noted to look for Keloidal tendency. 
 
Pre operative Work-up 
• CBC, BT,CT, Platelet Count, Blood sugar 
• Thyroid profile  
• Screening for Hepatitis-B, VDRL, HIV testing 
• Urine routine 
• Serum Creatinine, Blood Urea Nitrogen, SGOT, SGPT 
• Informed consent and photographs 
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 INCLUSION CRITERIA 
• Stable vitiligo 
• Willingness to be enrolled in the study 
 
EXCLUSION CRITERIA 
• Active vitiligo 
• Infection 
• H/s/o Herpes labialis 
• Keloidal tendency 
• Bleeding disorders 
• Overlying  altered thick skin- due to PUVA  
• Hypothyroidism 
• Pregnant and lactating females 
 
STUDY PROCEDURE: 
MINIATURE PUNCH GRAFTING: 
 
Instruments required: 
 2 and 2.5mm punches, 
 Small Jeweler`s  or graft holding forceps  
 Small scissors 
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PROCEDURE PROPER33-36: 
 
1)  The donor and recipient area surgically prepared 
2)  Tray is kept ready 
3)  Informed consent obtained 
4)  Pre procedure photographs taken 
5)  2% Lignocaine with or without adrenaline is infiltrated as 
local anaesthetic 
6)  The initial recipient chambers are made on or very close to 
the border of the lesion in order to minimize the achromic 
fissure. 
7)  The donor area is either upper lateral portion of thigh or 
gluteal region. In case of face, it is usually taken from the 
postauricular area. 
8)  In the donor area 2.5mm punch and in the recipient area 2.0 
mm punch were used.  This is done to prevent shrinking of the 
graft that is seen with same sized grafts. 
9)  The recipient area holes should be 1mm deeper than the 
thickness of the grafts to avoid cobblestone appearance. 
10) The excess fat in the graft should be trimmed.    
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11) The grafts are placed directly from donor to recipient area. This 
speeds up the procedure and lessens the chance of infection. 
Care is taken so that the graft edges are not folded, the tissue is 
not crushed or placed upside down. The needle of the syringe or 
the tip of the scissors is used for proper placement of grafts in 
the recipient chambers. 
 
12) Hemostasis is achieved by pressing a saline soaked gauze over 
the      area. 
11)  For the recipient area three layers of dressing from inside out 
are:  
 Chlorhexidine tulle, sterile gauzepad and elastoplast bandage.  
 For the  donor area also the same were applied. 
12)  One week of prophylactic systemic antibiotics given 
13)  Proper instructions for special areas like lips are necessary. To 
secure grafts    recipient area these patients are advised to take 
liquid diet for the first 24 hours preferably with a straw. Patients 
are allowed to take normal diet after this period. 
14)  The dressings are opened after 24 hours to look for any 
dislodgement of grafts: if any are found, they are replaced. 
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  15)  Finally after 7 days the dressings are removed. 
 
Post-op advice and Follow up: 
 Limit the movements for the first 48 hours. 
 After removal of the bandage, careful cleaning of the recipient area 
with gentle flushing of saline is advised.  
 Avoidance of using soap or rubbing the area with towel for 2 weeks 
was advised. The area should be allowed to dry by itself. 
 Post surgically the patients are exposed to sunlight  for few minutes 
2-3 times a week for about 3 weeks starting about 4th day after 
removal of bandage. 
 Topical Mometasone, alternate days topical Mometasone 0.1%  & 
Tacrolimus 0.1%, PUVASOL37/ PUVA/ NB-UVB38 were tried in 
response poor patients. 
 Patients were followed up fortnightly for first 2 months and then 
monthly. 
 Patients were advised to report immediately if they have severe 
itching, pain, persistent swelling or erythema and purulent 
discharge from the lesion. 
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SPLIT-THICKNESS SKIN GRAFTING: 
Instruments required: 
Artery forceps  
Sterile razor blade39 
Small scissors 
Jeweler`s forceps 
Small bowl 
Normal saline 
Gauze pieces 
Wooden board 
Glass slides  
Dermabrader  
Diamond fraise 
PROCEDURE PROPER19: 
Harvesting the graft: 
1)  The donor area is prepared for the surgery 
2)  The required area is marked with sterile marking pen. 
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3)  At least 10-25% larger area than the size of the vitiligo patch 
is marked, as there will be some contraction of the graft due to 
attached dermal elastic fibres. 
4)  Topical anaesthesia using a mixture of lidocaine 2.5% w/w 
and prilocaine 2.5% w/w cream under occlusion for at least 2 
hours is kept. 
5)  After the cream is wiped off, a pin-prick test is performed to 
judge the degree of anesthesia. If the effect is not satisfactory, 
field block is given with 2% lignocaine at the margins. 
6)  The sterile razor blade is held with the help of artery forceps. 
7)  The donor site is firmly stretched with the help of left hand. 
The blade-holding artery forceps is moved to and fro with the 
help of the right hand and a thin split-skin graft is harvested.  
Closely packed fine bleeding points is seen after taking the graft.  
8)  The donor area is covered with a non-adherent dressing and 
a pressure dressing is given. 
9)  The recipient area is infiltrated with 2% lignocaine without 
adrenaline. 
10)  After surgical cleansing, the area is first marked with a surgical 
pen.  
48 
 
11)  The skin is abraded with the help of dermabrader (either 
manual or electrical) a little deeper and it is stopped on seeing 
some coarse bleeding points. 
12)  The graft placed in the normal saline bowl is taken out and is 
stretched over the wooden board with the help of needle or 
Jeweler`s forceps.  A glass slide is taken and is kept over the 
epidermal surface of the graft, so that the dermal side of the 
graft is free. Then the glass slide is kept over the recipient area 
and the dermal side of the graft is well placed over the denuded 
area.  The free edge of the graft is stretched evenly at the 
periphery.  
13)  This is followed by a non-adherent dressing- chlorhexidine tulle, 
gauze piece and elastoplast.  
14)  One week of prophylactic systemic antibiotics given. 
15)  The dressing is removed at 24 hours to observe for any serous 
collection or hematoma, which is drained. Subsequently 
dressing is changed after a week.  
16)  The patient is then followed every fortnight for the first 2 
months and   monthly thereafter. 
                                                   
 
 
49 
 
                                       OBSERVATION AND  RESULTS 
 
Total number of Patients in the study group:  
Study Population:        
         This study included 50 patients, 25 males and 25 females. The 
youngest in the study was 12 years of age and the oldest patient was 56 
years of age. All satisfied the inclusion and exclusion criteria. 
Table 1- Age wise distribution of the study population: 
              Age group       No. of patients 
           11-20 years             10 
           21-30 years             26 
           31-40 years             12 
           41-50 years               1 
           51-60 years               1 
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 Chart no.1- age wise distribution of the study population 
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Table 2: Sex-wise distribution of the study group: 
Name of the 
procedure 
      Males           Females      Total  
Miniature punch 
grafting 
      13           12       25 
Split skin grafting       11           14       25 
                Chart no. 2-sex-wise distribution of the study population 
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Out of the total 50 patients, 20 patients had mucosal vitiligo over lips, 28 
patients had focal vitiligo over dorsum of foot/hand, eyelid, cheeks, 
forearm and legs, 1 patient had segmental vitiligo and 1patient had 
acrofacial vitiligo.  
Table 3 – Vitiligo type included in the study: 
S.No Type of vitiligo No.of patients 
1. Mucosal type          20 
2. Focal  type          28 
3. Segmental             1 
4. Acrofacial            1 
            Total          50 
 
Chart No.3 – Vitiligo type included in the study 
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Various studies have chosen 6 months to 2 years as a period of stability. In 
this study, except 4 patients all others had vitiligo lesions ≥ 1year stable. 
 
Miniature Punch grafting (MPG):  
 
Out of the 25 patients, in about 18 patients the colour of the grafts 
changed gradually from brown, dark brown to black. The upper scab fell 
off by 10-15 days which left a pinkish colour. This pink colour changed to 
skin colour by almost 3 weeks. In the remaining 7 patients the graft 
appeared to be skin coloured through out. At about 4th day after removal 
of  the dressing all  patients were asked to expose the grafted area for 3-5 
minutes in the sunlight 2-3 times a week. After 1-1 ½ months uniform 
perigraft pigmentation started  
appearing in 12 patients. So they were not given any other adjuvant 
therapy. In about 13 patients, the pigment islands remained static. For 
them adjuvant therapies like topical 0.1% Mometasone furoate were 
given for non-mucosal site and alternate days topical mometasone and 
topical 0.03% Tacrolimus were given to 4 patients with mucosal vitiligo. 
With the adjuvant therapy the lip vitiligo patients responded well. In the 
remaining 9 patients with non-mucosal vitiligo, 5 responded well with 
topical 0.1% Mometasone furoate. Out of the remaining 4, 2 were given 
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PUVA, 1 was given PUVASOL and 1 was given narrow band UV-B therapy.  
They all showed some response with adjuvant therapy. But one patient 
didn’t respond to any adjuvant therapy and in fact he gradually showed 
koebnerization at the donor site and depigmentation at the recipient site.  
This patient actually had stable disease over the dorsum of foot for the 
past 2 years.  
 
In the donor site, scarring was seen in 2 patients. Both were given topical 
steroids and showed some improvement. In the recipient site, immediate 
complication like graft displacement or rejection seen in 9 patients in 1 or 
2 miniature grafts within 24 hours or at 7 days. Despite this melanocyte 
transfer was not affected and good amount of repigmentation seen in 
course of time without regrafting. 3 patients had hyperpigmentation and 
1 had a variegated appearance.  In subsequent follow up, they also 
improved. None of the patients had secondary infection. 
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Table4- Pigmentation response with miniature punch grafting: 
          % of improvement       Grading            No. of patients 
< 25% response      Poor                    1 
25-50% response      Fair                   1 
50-75% response     Good                 19 
>75% response     Excellent                  4 
 
Split skin grafting (SSG): 
The results of the procedure are noted in the form of perigraft pigmentary 
spread, intensity of the pigmentation and the colour matching with 
surrounding normal skin. Donor site scarring occurred in one patient. 
Hyperpigmentation in the recipient site was seen with 3 patients. Static 
graft with stuck on appearance occurred in one patient. Graft rejection or 
necroses at the edges were seen in 6 patients and in 2 of them the entire 
graft was shed down at about 14 days. Despite that 4 of them had 
excellent repigmentation and 2 of them had good amount of 
repigmentation. 
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Table 5- Pigmentation response with split skin grafting: 
          % of improvement       Grading            No. of patients 
< 25% response      Poor                    0 
25-50% response      Fair                   1 
50-75% response     Good                 13 
>75% response     Excellent                 11 
  
In one patient with acrofacial type, the graft was static and 
hyperpigmented. It had a stuck on appearance and there were no pigment 
spread even after 9 months of follow up. One patient developed Keloidal 
scar at the recipient site and minimal scarring at the donor site. Three 
patients had hyperpigmentation at the recipient site. Six patients had 
milia which were removed by needling. Graft rejection and necrosis 
occurred in 6 patients. Out of them, 2 had almost complete necrosis and 4 
had necroses at the edges. Despite that the pigmentation was good to 
excellent in them. None of the patients had either donor site or recipient 
site secondary infection.  
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Comparison between the results of MPG and SSG: 
Response                   MPG                    SSG 
Poor & Fair                   2(8%)                      1(4%) 
Good & Excellent                 23(92%)                     24(96%) 
       Total                  25                     25 
 
Crosstabs 
                                           Case Processing Summary 
                                         Cases 
        Valid    Missing            Total 
   N Percent      N Percent    N Percent 
Procedure*Response    50 100%     0   .0%   50   100% 
 
                                               Procedure * Response Crosstabulation 
          Response     
      Total ≥Good Not good 
Procedure MPG       Count 
            %within the 
procedure 
   23 
92.0% 
        2 
        8.0% 
         25 
       100.0% 
SSG         Count 
           % within the 
procedure 
   24 
   96% 
        1 
        4.0% 
        25 
       100.0% 
Total                             Count  
                               % within the 
procedure 
   47 
   94% 
        3 
        6% 
        50 
        100.0% 
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Chi-Square tests 
  Value        Df Asym.Sig 
(2 sided) 
Exact.Sig 
(2 sided) 
Exact.Sig 
(1 sided) 
Pearson chi-Square 
Continuity 
correctiona 
Likelihood Ratio 
Fisher`s Exact Test 
Linear-by-Linear  
Association 
N of Valid cases 
 
 0.355b 
 0.000 
 
  0.361 
   
  0.348 
 
     50 
 
        1 
        1 
 
        1 
    
        1 
   0.552 
   1.000 
 
   0.548 
 
   0.556 
 
 
 
   1.000 
 
 
  0.500 
 
a. Computed only for a 2X2 table 
b. 2 cells (50.0%) have expected count less than 5. The minimum 
expected count is 1.50 
 
The p value in this test is 0.552. Hence the difference between the results 
of miniature punch graft and split skin graft is not significant in this study. 
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              Incidence of complications in both the procedure: 
Name of the 
complication  
Miniature punch 
grafting 
Split skin grafting 
DONOR SITE: 
Infection             0             0 
Scar              2(8%)             1(4%) 
Koebnerization              1(4%)             0 
Hyperpigmentation              0             0 
RECIPIENT SITE: 
Infection             0             0 
Hyperpigmentation              3(12%)             3(12%) 
Cobbling             2(8%)             0 
Variegation             1(4%)             0 
Scar             2(8%)             1(4%) 
Static graft             13(52%)             1(4%) 
Depigmentation              1(4%)             0 
Milia              0             6(24%) 
Graft displacement/ 
rejection 
            9(36%)             6(24%) 
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                           Procedure * Scar  Crosstabulation 
               Scar     
      Total Present        Not 
Procedure MPG       Count 
            %within the 
procedure 
       2 
       8.0% 
        23 
       92.0%  
         25 
       100.0% 
SSG         Count 
           % within the 
procedure 
       1 
       4.0% 
         24 
         96.0% 
        25 
       100.0% 
Total                             Count  
                               % within the 
procedure 
       3 
       6.0% 
 
         47 
         94.0% 
        50 
        100.0% 
 
                                             Chi-Square tests 
  Value        Df Asym.Sig 
(2 sided) 
Exact.Sig 
(2 sided) 
Exact.Sig 
(1 sided) 
Pearson chi-Square 
Continuity 
correctiona 
Likelihood Ratio 
Fisher`s Exact Test 
Linear-by-Linear  
Association 
N of Valid cases 
 
 0.355b 
 0.000 
 
  0.361 
   
  0.348 
 
     50 
 
        1 
        1 
 
        1 
    
        1 
   0.552 
   1.000 
 
   0.548 
 
   0.556 
 
 
 
   1.000 
 
 
  0.500 
a. Computed only for a 2X2 table 
b. 2 cells (50.0%) have expected count less than 5. The minimum 
expected count is 1.50 
The p value for this complication (scar) is 0.552 which is not <0.005. Hence 
this is not significant. 
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                                                 Procedure * Static graft  Crosstabulation 
         Static graft     
      Total Present        Not 
Procedure MPG       Count 
            %within the 
procedure 
       13 
       52.0% 
        12 
        48.0%  
         25 
       100.0% 
SSG         Count 
           % within the 
procedure 
       1 
       4.0% 
         24 
         96.0% 
        25 
       100.0% 
Total                             Count  
                               % within the 
procedure 
       14 
       28.0% 
 
         36 
         72.0% 
        50 
        100.0% 
                                             Chi-Square tests 
  Value        Df Asym.Sig 
(2 sided) 
Exact.Sig 
(2 sided) 
Exact.Sig 
(1 sided) 
Pearson chi-Square 
Continuity 
correctiona 
Likelihood Ratio 
Fisher`s Exact Test 
Linear-by-Linear  
Association 
N of Valid cases 
 
 14.286b 
 12.004 
 
 16.281 
  
 14.000 
 
   50 
        1 
        1 
 
        1 
    
        1 
   .000 
   .001 
 
   .000 
 
   .000 
 
 
 
   .000 
 
 
  .000 
a. Computed only for a 2X2 table 
b. 2 cells (.0%) have expected count less than 5. The minimum 
expected count is 7.00 
 
The p value for this complication (static graft) is 0.000 which is <0.005. 
Hence it is significant. But the repigmentation improved with adjuvant 
therapy and the end result was not affected. 
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                                     Procedure * Graft rejection  Crosstabulation 
         Graft rejection     
      Total Present        Not 
Procedure MPG       Count 
            %within the 
procedure 
       9 
       36.0% 
        16 
        64.0%  
         25 
       100.0% 
SSG         Count 
           % within the 
procedure 
       6 
       24.0% 
         19 
         76.0% 
        25 
       100.0% 
Total                             Count  
                               % within the 
procedure 
       15 
       30.0% 
 
         35 
         70.0% 
        50 
        100.0% 
 
                                                 Chi-Square tests 
  Value        Df Asym.Sig 
(2 sided) 
Exact.Sig 
(2 sided) 
Exact.Sig 
(1 sided) 
Pearson chi-Square 
Continuity 
correctiona 
Likelihood Ratio 
Fisher`s Exact Test 
Linear-by-Linear  
Association 
N of Valid cases 
 
    .857b 
    .381 
 
    .862 
  
    .840 
 
      50 
        1 
        1 
 
        1 
    
        1 
   .355 
   .537 
 
   .353 
 
   .359 
 
 
 
   .538 
 
 
  .269 
a. Computed only for a 2X2 table 
b. 2 cells (.0%) have expected count less than 5. The minimum 
expected count is 7.50 
 
The p value in this complication (graft rejection) is 0.355 which is not 
<0.005. Hence it is not significant. 
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                 Focal vitiligo, dorsum of hand-Miniature punch grafting 
                 
                focal vitiligo over dorsum of hand              after miniature punch grafting 
 
After 6 weeks 
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MINIATURE PUNCH GRAFTING  LIP VITILIGO  
         
                           2 weeks        6 weeks  
 
     
8 weeks     10 weeks  
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SPLIT SKIN GRAFTING  LIP VITILIGO 
 
 
Immediate post op  
 
After 3 weeks  
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SPLIT SKIN GRAFTING  LIP VITILIGO 
 
Before SSG 
 
After SSG 
 
After 4 weeks  
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FOCAL VITILIGO – DORSUM OF THE FOOT 
 
Immediate post op  
 
2 weeks  
 
4 weeks 
68 
 
 
 
 
MINIATURE PUNCH GRAFTING  LIP VITILIGO  
 
           
Before MPG     After MPG 
               
After 4 weeks       After 8 weeks 
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SPLIT SKIN GRAFTING  LIP VITILIGO 
 
 
Before SSG 
 
 
 
After 1 ½  months  
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COMPLICATIONS 
 
Scarring at the donor site  after MPG 
 
Graft displacement After SSG 
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DISCUSSION 
In spite of the considerable advancement in basic understanding of 
the disease process and the treatment protocol, Vitiligo has continued to 
elude researchers over the years. Conventional medical therapy remains 
beleaguered by unpredictable and inadequate outcomes. When the 
disease becomes refractory to conservative therapy, transplantation 
techniques are the only options left to replenish the lost melanocytes. 
 
Among the various surgical methods for vitiligo, miniature punch 
grafting and split skin grafting are some of the simplest methods that can 
be easily done at a resource poor settings with a good result. 
 
Miniature punch grafting: 
 
In a study by S S Savant36, he showed that 86% of cases had total 
repigmentation with excellent cosmetic colour match.  
 
KG Singh40 et al showed fair to excellent results in 87.5%. 
 
In our study, 92% had good to excellent repigmentation. Vitiligo of any 
site and size can be treated by this method, with multiple sittings in bigger 
areas. In our study we chose mostly localized type with good stability of 
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the disease. Except 4 patients, all other had stability equal to or more than 
one year.  
 
Cobblestoning, the most common side effect seen with punch 
grafting was initially seen in almost all cases up to the first month of 
follow up. But after 3 months it spontaneously disappeared in most of 
them and at last after 6 months it was seen only in 8% of cases.  All the 
patients were advised sunexposure for 3-5 minutes twice a week. During 
assessment at 6 weeks, if the perigraft pigmentation if started well, they 
were not given any adjuvant therapy. If pigment spread is poor adjuvant 
therapy was given. 
 
Falabella 5 had used 1-1.2mm punches in his study. In our study we 
had used 2-2.5mm punches with equally good results.  
 
In the year 1972, Orentriech and Selmanwitz43 showed maximum 
pigment spread as 1mm. Whereas Savant8 in 1992, showed 15mm and 
Lahiri34 et al in 2005 showed 12mm maximum pigment spread. 
In our study we had an average of 10 mm maximum pigment 
spread without adjuvant therapy. With adjuvant therapy the average 
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maximum pigment spread was 14mm which was consistent with other 
studies. 
Split Skin Grafting: 
 
Split thickness skin grafting is very popular for its better colour, 
texture match, faster results and highest success mean rate. 
 
Farah et al41 reported satisfactory response with good colour match 
and minimal complications in 50 patients treated with split skin grafting. 
 
In our study, among 25 patients 96% of them had good to excellent 
results.  The pigment spread was noticed later as compared to miniature 
punch grafting, but the repigmentation was very good without any 
adjuvant therapy. 
 
Somesh gupta et al19 showed that it is best to dermabrade the 
recipient areas before the donor area is harvested. This gives some 
valuable time for the bleeding to stop at the recipient area and provides 
absolutely fresh graft. 
Except for a bigger graft, for all other cases we also followed the same 
technique. 
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In our study except 3 patients, all others responded very well 
without any adjuvant therapy. With adjuvant therapy 2 responded well 
but the remaining one had hyperpigmentation at the graft site with no 
pigment spread at all. 
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CONCLUSION 
 To conclude Miniature Punch grafting and Split skin grafting are 
easy to perform, cost effective procedure that gives excellent 
results with minimal side effect provided we choose the right 
candidate for treatment. 
 Both these surgical methods do not require any laboratory 
technicians, expensive equipments or chemicals. 
 The results obtained depended upon patient selection with 
achievement of excellent pigmentation when the lesions are stable, 
focal or segmental and over areas with minimum mobility. 
  Miniature punch grafting is not only an easy, safe and least 
expensive method, but it is one of the most effective treatment 
options in treating stable and recalcitrant vitiligo. 
  Cobblestoning, the commonest side effect with punch grafting, can 
be minimized by using miniature punch grafting technique using 2-
2.5mm punches. 
 Though miniature punch graft is easy and safe, pigment dispersion 
takes a longer time to achieve. So immediate cosmetic results are 
less compared to split skin grafting hence patient preference is 
more for the latter. 
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 This problem can be minimized by the use of adjuvant therapies. 
 Split thickness skin grafting gives almost immediate results, but 
requires expertise in harvesting the graft. 
 Pigmentation is uniform with split thickness skin grafting.  
  Cobblestoning, common with minigrafting, does not occur in SSG. 
 Adjuvant therapy is not routinely needed for split skin grafting 
 Graft necrosis though is more common with split skin grafting, but 
repigmentation was also observed in such grafts due to the 
adjuvant effect of dermabrasion done for preparation of the graft 
site. 
 The most significant factor influencing success with split skin graft 
was mobility of the recipient site with poor results at highly mobile 
recipient sites. 
 Thus, even in the absence of adequate resources, both the 
surgeries can be done with almost similar good results. 
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 Miniature Punch 
grafting 
Split Skin grafting 
Success rate                92%              96% 
Cobbling                 + 
(minimized by using 
smaller punches) 
               - 
Milia                 -                 +        
Graft rejection                 +             ++++ 
Immediate results              No              Yes 
Uniform pigment 
dispersion 
             No             Yes 
Cosmetically             Good         Excellent 
Palms & soles            Useful         Not useful 
Mobile areas       Can be done Very difficult to 
maintain the graft 
Adjuvant therapy       Needed in many Usually not needed 
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PROFORMA 
• NAME:                                     AGE:          SEX: 
• OCCUPATION:                         INCOME: 
• CHIEF COMPLAINTS: 
 
• History of present illness: 
 
 
 
• Past history: 
• Family history: 
• Personal history: 
• Examination: 
 
     DIAGNOSIS: 
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CONSENT FORM 
• Mr./Mrs./Miss 
• Age 
• Address  
• Phone: 
• Name of the procedure 
• I undersigned Mr./Mrs./Miss 
•  
    Have been explained regarding above said procedure in my regional language. I am 
fully aware of the possible side effects and risks involved in this procedure. I am also 
aware that this particular procedure may not always be successful and no guarantee 
can be made for successful outcome of such procedure. 
 
I have explained that this procedure will be performed by Dr.T.Vanathi. 
 
I also given my consent that during this procedure if any complication arises, I may be 
given any emergency treatment best suitable to me without asking my prior 
permission.   
 
I further state that I have carefully read and understood all the information provided in 
this form and under fully conscious mind I hereby give my written consent for the said 
procedure with its risks involved. 
 
Signature  of Patient/thumb impression 
Signature of Parents/Guardian(for minors)    
Name &Relationship if signed by other than parent 
 
Witness: 
 
Name:                                                      
 Signature: 
 
Date:  
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